4-chloro-1-methylindole-3-carboxaldehyde | 338760-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-chloro-1-methylindole-3-carboxaldehyde
• 英文别名: 4-chloro-1-methyl-1H-indole-3-carboxaldehyde；4-chloro-1-methylindole-3-carbaldehyde
• CAS: 338760-69-3
• 化学式: C₁₀H₈ClNO
• 分子量: 193.633
• InChiKey: LVIDTXMLMRTBNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-chloro-1-methylindole-3-carboxaldehyde 在 lithium aluminium tetrahydride 、 ammonium acetate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 N-(2-(4-chloro-1-methyl-1H-indol-3-yl)ethyl)-4-methylbenzenesulfonamide
  参考文献：
  名称：

  CuCl2/TBHP-mediated direct chlorooxidation of indoles

  摘要：

  CuCl2/TBHP-mediated direct chlorooxidation of indole derivatives under simple aerobic conditions was reported, leading to facile preparations of a range of 3,3-disubstituted 3-chlorooxindoles in good yields and selectivities. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2015.05.065
• 作为产物：
  描述：

  4-氯吲哚 在 sodium hydride 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-chloro-1-methylindole-3-carboxaldehyde
  参考文献：
  名称：

  1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors

  摘要：

  KDR kinase inhibition is considered to play an important role in regulating angiogenesis, which is vital for the survival and proliferation of tumor cells. Recently we disclosed a structure-based kinase inhibitor design strategy which led to the identification of a new class of VEGFR-2/KDR kinase inhibitors bearing heterocyclic substituted pyrazolones as the core template. Instability in a rat S9 preparation and poor iv PK profiles for most of these inhibitors necessitated exploration of new pyrazolones to identify new analogs with improved metabolic stability. Optimization of the heterocyclic moiety led to the identification of the thiadiazole series of pyrazolones (D) as potent VEGFR-2/KDR kinase inhibitors. SAR modifications, kinase selectivity profiling, and structural elements for improved PK properties were explored. Oral bioavailability up to 29% was achieved in the rat. Modeling results based on the Glide XP docking approach supported our postulation regarding the interaction of the lactam segment of the pyrazolones with the hinge region of the KDR kinase. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.054

文献信息

• Heterocyclic substituted pyrazolones
  申请人：Cephalon, Inc.

  公开号：US06455525B1

  公开（公告）日：2002-09-24

  The present invention is directed to novel heterocyclic substituted pyrazolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The invention is also directed to intermediates and processes for making these novel compounds.

  本发明涉及新颖的杂环取代吡唑酮，包括含有这些化合物的药物组合物、诊断试剂盒、检测标准或试剂，以及将其用作治疗的方法。该发明还涉及制备这些新化合物的中间体和方法。
• Fab I inhibitors
  申请人：Burgess J. Walter

  公开号：US20060116394A1

  公开（公告）日：2006-06-01

  Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.

  本发明揭示了一种Fab I抑制剂，可用于治疗细菌感染。
• Compositions comprising multiple bioactive agents, and methods of using the same
  申请人：Berman M. Judd

  公开号：US20060142265A1

  公开（公告）日：2006-06-29

  In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

  本发明的一部分涉及含有FabI抑制剂和至少一种其他生物活性剂的组合物。另一部分，本发明涉及含有I-III式化合物和至少一种其他抗菌剂的抗菌组合物。
• Fab I Inhibitors
  申请人：Burgess Walter J.

  公开号：US20090221699A1

  公开（公告）日：2009-09-03

  Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.

  本发明揭示了一种Fab I抑制剂，可用于治疗细菌感染。
• Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same
  申请人：BERMAN JUDD M.

  公开号：US20120010127A1

  公开（公告）日：2012-01-12

  In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

  本发明的一部分涉及包含FabI抑制剂和至少一种其他生物活性剂的组合物。另一部分涉及包含I-III式化合物和至少一种其他抗菌剂的抗菌组合物。